Understanding the pathophysiology of GBS UTI in diabetes
了解糖尿病 GBS UTI 的病理生理学
基本信息
- 批准号:10495253
- 负责人:
- 金额:$ 17.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAdhesionsAdultBacteremiaBacteriaBacterial AdhesinsBacteriuriaBiological AssayBladderCellsCharacteristicsCytolysinsDataDiabetes MellitusDiabetic NeuropathiesDiabetic mouseDiseaseEpithelialExhibitsExploratory/Developmental GrantExposure toFunctional disorderFutureGene ExpressionGenesGenetic ModelsGenetic TranscriptionGestational DiabetesGlucoseGlycosuriaGoalsHemolysinHemolysisHistologyHistopathologyHumanHyperglycemiaImmuneImmune responseImmunosuppressionIn VitroIncidenceIndividualInfectionInfiltrationInsulin-Dependent Diabetes MellitusIntegration Host FactorsKidneyKnowledgeLifeMetabolicMonitorNon-Insulin-Dependent Diabetes MellitusOrganOutcomePathogenesisPhysiologicalPhysiologyPolysaccharidesPredispositionPregnant WomenProductionPublicationsPublishingPyelonephritisRegulator GenesResearchResistanceRiskSepsisShapesSialic AcidsSiteSkinSpleenStreptococcus Group BStreptozocinSurfaceTimeTissuesToxinType 2 diabeticUrinary RetentionUrinary tractUrinary tract infectionUrineUropathogenVirulenceVirulence Factorsantimicrobial peptide LL-37ascending urinary tract infectioncapsulecomorbiditycytokinecytotoxicitydb/db mousediabeticexperimental studyfitnessgastrointestinalgene networkglycemic controlimmunopathologymouse modelmutantnephrotoxicityneutrophilnon-diabeticnovelpathogenpleiotropismreproductiveside effectsmall molecular inhibitortherapeutically effectivetranscriptometranscriptome sequencingtype I diabeticurinaryvaginal microbiota
项目摘要
ABSTRACT
Diabetic individuals are more susceptible to urinary tract infections (UTI). Specifically, the risk of UTI caused by
Gram positive Streptococcus agalactiae (Group B Streptococcus, GBS) is significantly increased in diabetic
individuals. In addition, diabetes also facilitates the progression of GBS-UTI to severe and potentially deadly
outcomes such as pyelonephritis, bacteremia, and sepsis. We hypothesize that “the diabetic urinary
microenvironment facilitates infection of the urinary tract 1) by augmenting virulence of uropathogenic
bacteria and 2) by suppressing host immune defenses.” To address this hypothesis, we have proposed
targeted exploratory studies, in alignment with the scope of R21 mechanism, to elucidate GBS factors and host
urinary immune defenses central to GBS-UTI pathogenesis in two mechanistically distinct murine models of
hyperglycemia: 1) STZ-induced type 1 diabetes and 2) db/db, a genetic model of type 2 diabetes.
Previous research has characterized myriad GBS virulence factors such as surface adhesins, pore forming
toxins, and gene regulators facilitating GBS survival and virulence in the urinary tract. Studies using mouse
model of ascending UTI have also revealed distinctive urinary immune responses induced by GBS-UTI.
However, two important knowledge gaps exist in our understanding of GBS-UTI pathogenesis in diabetes:
1) the pleiotropic effects of host diabetic urinary microenvironment on GBS physiology are undefined and
2) specific host mechanisms responsible for increased urinary GBS burden observed in diabetic mice are not
fully deciphered. To fill these knowledge gaps we propose:
Specific Aim 1 Identify and characterize specific GBS factors important for uropathogenesis in diabetic
mice. We will compare RNA-sequencing profiles of GBS isolated from diabetic and non-diabetic urinary tracts
to identify differentially transcribed virulence, regulatory and metabolic gene expression networks. The
experiments proposed in SA1 are founded on our published results that in vitro exposure to moderate
glycosuria significantly increases GBS virulence.
Specific Aim 2 Evaluate pathophysiology of GBS-UTI in type 1 and type 2 diabetic mice. In this aim we
will induce ascending UTI by inoculating GBS into STZ-type 1 and db/db type 2 diabetic mice and their non-
diabetic littermates and examine differences in disease parameters such as bacterial burden, cytokine
production, immune cell infiltration and histopathology of the urinary tract. The experiments in SA2 are founded
on supporting data that at 24h after intravesicular inoculation with GBS, db/db diabetic mice exhibit significantly
higher bacterial burden in bladder and kidneys and increased dissemination to spleen.
In addition to heralding significant advances in the field of GBS-UTI, our results will pave the way for research
into the effects of diabetes on the pathogenesis of other uropathogens, identifying novel host/pathogen targets
against which small molecular inhibitors may ultimately be developed as effective therapeutics to treat UTI.
抽象的
糖尿病患者更容易受到尿路感染(UTI)。具体而言,由
糖尿病患者的革兰氏阳性链球菌(B组链球菌,GBS)显着增加
此外,糖尿病还促进了GBS-UTI到严重且可能致命的进展
肾上腺炎,细菌和败血症等结果。我们假设“糖尿病尿
微环境促进尿路的感染1)通过增强尿道病病毒
细菌和2)通过抑制宿主的免疫防御。”为了解决这一假设,我们提出了
针对R21机制范围的针对探索性研究,以阐明GBS因子和宿主
在两个机械上不同的鼠模型的GBS-UTI发病机理的中心防御
高血糖:1)STZ诱导的1型糖尿病和2)DB/DB,这是2型糖尿病的遗传模型。
先前的研究表征了无数GBS病毒因子,例如表面粘合剂,孔形成
毒素和基因调节剂支持尿路中的GBS存活和病毒。使用鼠标的研究
上升UTI的模型还揭示了GBS-UTI引起的独特尿免疫反应。
但是,在我们对糖尿病中GBS-UTI发病机理的理解中,存在两个重要的知识差距:
1)宿主糖尿病尿液微环境对GBS生理学的多效性影响不确定,并且
2)在糖尿病小鼠中观察到的泌尿GB燃烧增加的特定宿主机制不是
为了填补这些知识空白,我们提出了:
特定目标1识别并表征特定的GBS因子对糖尿病中尿路病重要的重要
老鼠。我们将比较从糖尿病和非糖尿病尿道中分离出的GB的RNA测序曲线
识别不同转录的病毒,调节性和代谢基因表达网络。
SA1中提出的实验建立在我们发布的结果上,该结果体外暴露于现代
糖尿症显着增加了GBS病毒。
特定目标2评估1型和2型糖尿病小鼠中GBS-UTI的病理生理学。在这个目标中我们
将通过将GBS接种到STZ型1和DB/DB 2型糖尿病小鼠及其非 -
糖尿病窝窝和检查疾病参数的差异,例如细菌燃烧,细胞因子
尿路的产生,免疫细胞浸润和组织病理学。 SA2中的实验是建立的
关于支持GBS经内接种后24H的数据,DB/DB糖尿病小鼠显着暴露
膀胱和肾脏中较高的细菌燃烧,并增加对索伦的传播。
除了预示GBS-UTI领域的重大进展外,我们的结果还将为研究铺平道路
进入糖尿病对其他尿道病的发病机理的影响,鉴定出新的宿主/病原体靶标
最终可以将小分子抑制剂作为治疗UTI的有效疗法开发。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Systematic Review of Literature Examining Bacterial Urinary Tract Infections in Diabetes.
- DOI:10.1155/2022/3588297
- 发表时间:2022
- 期刊:
- 影响因子:4.3
- 作者:Paudel, Santosh;John, Preeti P.;Poorbaghi, Seyedeh Leila;Randis, Tara M.;Kulkarni, Ritwij
- 通讯作者:Kulkarni, Ritwij
Glycosuria Alters Uropathogenic Escherichia coli Global Gene Expression and Virulence.
- DOI:10.1128/msphere.00004-22
- 发表时间:2022-06-29
- 期刊:
- 影响因子:4.8
- 作者:
- 通讯作者:
A Systematic Review of the Literature Examining the Effects of Cigarette Smoke and e-Cigarette Vapor on the Virulence of Human Pathogenic Bacteria.
- DOI:10.3390/ijerph191912518
- 发表时间:2022-09-30
- 期刊:
- 影响因子:0
- 作者:Bagale, Kamal;Kulkarni, Ritwij
- 通讯作者:Kulkarni, Ritwij
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ritwij Kulkarni其他文献
Ritwij Kulkarni的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ritwij Kulkarni', 18)}}的其他基金
Understanding the pathophysiology of GBS UTI in diabetes
了解糖尿病 GBS UTI 的病理生理学
- 批准号:
10348280 - 财政年份:2021
- 资助金额:
$ 17.17万 - 项目类别:
相似国自然基金
坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
- 批准号:
- 批准年份:2022
- 资助金额:45 万元
- 项目类别:面上项目
坚持还是转型?反馈驱动的创业者机会信念认知更新及响应决策机理
- 批准号:72272131
- 批准年份:2022
- 资助金额:45.00 万元
- 项目类别:面上项目
不确定性下创业团队能量和抗逆力对创业坚持的权变影响研究
- 批准号:72162025
- 批准年份:2021
- 资助金额:29 万元
- 项目类别:地区科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
创造性思维中灵活性和坚持性动态交互的神经基础
- 批准号:32100850
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
相似海外基金
Multifunctional Roles of AgI/II Family Proteins
AgI/II 家族蛋白的多功能作用
- 批准号:
10750344 - 财政年份:2023
- 资助金额:
$ 17.17万 - 项目类别:
2023 Microbial Adhesion and Signal Transduction Gordon Research Conferences and Seminar
2023年微生物粘附和信号转导戈登研究会议和研讨会
- 批准号:
10666171 - 财政年份:2023
- 资助金额:
$ 17.17万 - 项目类别:
The Role of Staphylococcus aureus SasD in Lung
金黄色葡萄球菌 SasD 在肺中的作用
- 批准号:
10748089 - 财政年份:2023
- 资助金额:
$ 17.17万 - 项目类别:
Novel Biofilm Paradigm Explaining Clinical Implant-Associated Illness.
解释临床植入相关疾病的新型生物膜范式。
- 批准号:
10515767 - 财政年份:2022
- 资助金额:
$ 17.17万 - 项目类别: